香港共识声明管理不可切除的肝细胞癌

StephenW

Liver Cancer. 2018 Mar;7(1):40-54. doi: 10.1159/000485984. Epub 2018 Jan 25.
Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.
Cheung TT1, Kwok PC2, Chan S3, Cheung CC4, Lee AS5, Lee V6, Cheng HC7, Chia NH8, Chong CCN9, Lai TW10, Law ALY11, Luk MY6, Tong CC6, Yau TCC12.
Author information

1
    Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
2
    Department of Radiology and Imaging, Queen Elizabeth Hospital, Hong Kong, China.
3
    Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
4
    Department of Surgery, Tuen Mun Hospital, Hong Kong, China.
5
    Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China.
6
    Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
7
    Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.
8
    Department of Surgery, Queen Elizabeth Hospital, Hong Kong, China.
9
    Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
10
    Department of Surgery, Princess Margaret Hospital, Hong Kong, China.
11
    Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
12
    Department of Medicine and Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

Abstract
Background:

Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong due to the high prevalence of chronic hepatitis B infection. Liver cancer is the fourth most common cancer and the third most common cause of cancer death. Due to the high case load, there is a high level of local expertise in treating HCC, and the full spectrum of treatment modalities is available. This document summarizes how these modalities should be used based on the latest evidence.
Summary:

In 2 meetings held in early 2017, a multidisciplinary group of Hong Kong clinicians, including liver surgeons, interventional radiologists, clinical oncologists, and medical oncologists, met to update local consensus statements for management of HCC. These statements are based on the latest evidence and give detailed guidance on how to deploy these modalities, in particular for cases of HCC which are not suited to surgical resection.
Key Messages:

These statements give detailed information on how to decide if a patient is a candidate for resection, methods to improve candidacy for resection, and guidance for use of various nonsurgical interventions to manage patients ineligible for resection.
KEYWORDS:

Consensus; Hepatocellular carcinoma; Hong Kong; Unresectable HCC

PMID:
    29662832
PMCID:
    PMC5892367
    [Available on 2019-03-01]
DOI:
    10.1159/000485984

StephenW

肝癌。 2018年3月; 7（1）：40-54。 doi：10.1159 / 000485984。电子邮件2018年1月25日。
香港共识声明管理不可切除的肝细胞癌。
Cheung TT1，Kwok PC2，Chan S3，Cheung CC4，Lee AS5，Lee V6，Cheng HC7，Chia NH8，Chong CCN9，Lai TW10，Law ALY11，Luk MY6，Tong CC6，Yau TCC12。
作者信息

1
    香港大学玛丽医院外科，香港，中国。
2
    香港伊利沙伯医院放射科和影像科。
3
    香港中文大学威尔斯亲王医院临床肿瘤科，中国香港。
4
    香港屯门医院外科。
五
    香港屯门医院肿瘤科。
6
    香港大学玛丽医院临床肿瘤科，中国香港。
7
    香港伊利沙伯医院临床肿瘤科。
8
    中国香港伊利沙伯医院外科。
9
    香港中文大学外科学系，香港，中国。
10
    中国香港玛嘉烈医院外科。
11
    临床肿瘤学，东区尤德夫人那打素医院，中国香港。
12
    香港大学玛丽医院内外科，香港，中国。

抽象
背景：

由于慢性乙型肝炎感染的高发病率，肝细胞癌（HCC）在香港非常普遍。肝癌是第四大常见癌症，也是癌症死亡的第三大常见原因。由于病例负荷高，在治疗HCC方面有很高的本地专业知识，并且可以提供全方位的治疗方式。本文件根据最新的证据总结如何使用这些模式。
概要：

在2017年初举行的2次会议上，包括肝脏外科医生，介入放射科医师，临床肿瘤学家和医学肿瘤学家在内的多学科香港临床医师小组开会，更新了当地有关HCC管理的共识声明。这些声明基于最新的证据，并就如何部署这些模式提供详细指导，特别是对于不适合手术切除的HCC病例。
关键信息：

这些声明提供了如何确定患者是否为切除术候选人的详细信息，改善切除术候选人的方法，以及使用各种非手术干预措施来管理不符合切除术要求的患者的指导。
关键词：

共识;肝细胞癌;香港;无法切除的HCC

结论：
    29662832
PMCID：
    PMC5892367
    [2019-03-01可用]
DOI：
    10.1159 / 000485984